

January 13, 2024

BSE Ltd.
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 001

BSE Scrip Code: 506943 Stock Symbol: JBCHEPHARM

Dear Sir,

Sub.: Disclosure under Regulation 30 of the SEBI (Listing obligations and Disclosure Requirements), Regulations, 2015

Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), this is to inform that the Company has received an order from National Pharmaceutical Pricing Authority.

The relevant information in the format prescribed by SEBI vide its circular no. SEBI/HO/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, is as under:

Name of the authority	National Pharmaceutical Pricing Authority (NPPA)
Nature and details of the action(s) taken, initiated or order(s) passed	The NPPA has directed the Collector to recover alleged overcharged amount with interest, amounting to Rs. 1.11 crores, under Essential Commodities Act
Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority	12 th January 2024
Details of the violation(s)/contravention(s) committed or alleged to be committed	Alleged Overcharging



Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible

The Company has been advised that it has good case on merits. The Company will prefer an appropriate remedy against the order.

There is no impact on financial, operations or other activities of the Company due to this order.

We request you to take the above on record.

Thanking you,

Yours faithfully, For J.B. Chemicals & Pharmaceuticals Ltd.

Sandeep Phadnis
Vice President – Secretarial
& Company Secretary